ARTICLE | Clinical News
Xerecept corticorelin: Phase I/II data
July 9, 2012 7:00 AM UTC
Data from 14 evaluable pediatric patients in an open-label, U.S. Phase I/II trial showed that twice-daily subcutaneous Xerecept reduced daily dexamethasone dosing requirements by >50% in 10 patients, ...